NASDAQ: WGS

GeneDx (WGS) Stock Analysis & Forecast

Oct 12 close

$63.82−3.51 (−5.2%)
Add to Watchlist

Gekko Brief

AI summaryOct 12 close

This week's news on GeneDx centers on its genomic newborn screening work, with new findings presented at ICoNS 2026 highlighting advances in rare disease diagnosis, alongside a comparison piece weighing GeneDx against peer Brookdale Senior Living across profitability, earnings and analyst recommendations. A separate report noted shares rising 4.3% to $76.27 on 5 October, described as a recovery from a recent decline, tied to a GF Score of 67.

GeneDx now trades at $63.82, down 5.2%, sitting below both its 50-day average of $81.98 and its 200-day average of $76.31, with a one-month return of -25.2% and a one-year return of -49.7%. The GekkoIndex reads 68.3, placing the stock in the Accumulation zone, up 3.5 over five days. Price sits 26.3% below Gekko Fair Value of $86.61.

GeneDx reports earnings on 27 October 2026, 15 days away, falling inside a typical 20-trading-day holding window; the last print on 3 August showed EPS of $0.01 against a -$0.19 estimate, with an 8.9% reaction, and the company has beaten estimates in 7 of 8 recent quarters, with an average absolute reaction of 27.7%. Seasonality over the next 20 trading days has averaged +2% across 5 years, positive in 4 of them. Analyst consensus from 7 firms carries a $93.50 target, all rated buy. No insider, Congress or unusual options activity appears in the current window.

Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.

GeneDx price vs fair value

$86.61$63.82Oct ’25Apr ’26Oct ’26
Close $63.82200-day averageGekko Fair Value $86.61

GeneDx quick facts

Market cap
$1.90B
P/E ratio
—
Forward P/E
63.3
EPS, TTM
−$3.63
Revenue, TTM
$454.4M
Profit margin
-23.4%
Dividend yield
—
Beta
1.97
Volume
490,417 avg 839,135
1-year return
−49.7%
Typical daily move
±9.3%
Typical 20-day move
±19.8%
50-day average
$81.98
200-day average
$76.31
Next earnings
Oct 27
Shares outstanding
29.82M
52-week range
$32.21$170.87

GeneDx swing-trade checklist

GeneDx scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive1 mixed1 headwind

  • Trendmixed

    Averages disagree

    Close $63.82 sits between the 50-day ($81.98) and 200-day ($76.31) averages, or the averages disagree.

    See the chart
  • GekkoIndexsupportive

    68.3, Accumulation

    Reading 68.3 is in the Accumulation zone.

    See the GekkoIndex
  • Fair valuesupportive

    26.3% below

    Price is 26.3% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings riskheadwind

    Reports in 15 days

    Reports on Oct 27, 2026, 15 days away — inside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +2.0% on average

    From this point in the calendar, the next 20 trading days averaged +2% over 5 years, rising in 4 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

GeneDx stock chart and price history

GeneDx closed at $63.82 on Oct 12, 2026, −49.7% over the past year, inside a 52-week range of $32.21 to $170.87.

5Y and weekly in Gekko
Close50-day average200-day averageVolume
GeneDx share price, past year, with 50-day and 200-day moving averages and volume$50$75$100$125$150$175NovDecJan 2026FebMarAprMayJunJulAugSepOct63.82

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−25.2%
3 months
+2.2%
6 months
+4.7%
1 year
−49.7%
The full WGS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open WGS in Gekko

Follow GeneDx through every session

Put WGS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track WGS in GekkoFree for 7 days. No credit card required.

About GeneDx

GeneDx operates in the genomics space, running genetic tests that help identify conditions in patients, with particular strength in cases involving children and uncommon inherited disorders. Much of this diagnostic work relies on sequencing a person's whole exome or entire genome, which has become the trait most associated with the company.

Alongside the lab testing itself, GeneDx offers services built around organizing and delivering genetic data and information. It has also built a software platform using artificial intelligence that reads and interprets results from next generation sequencing, turning raw genetic data into clinical reports. This technology is applied not just to rare disease cases but also to assessing inherited cancer risk and other hereditary conditions.

The company traces its founding back to 2000 and runs its operations out of Stamford, Connecticut. Investors can find its stock listed on the NASDAQ under the ticker WGS.

Listed
NASDAQ
Sector
Health services
Industry
Medical/Nursing services
Website
genedx.com

GeneDx GekkoIndex: the smart money zone

GeneDx’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 68.3, in the Accumulation zone, up 3.5 points over five sessions.

010068.3Accumulation

Up 3.5 points over five sessions.

Reading for Oct 12, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying29+1.0%+6.0%+9.5%+1.8%
Accumulation (current zone)148+3.4%+4.4%+1.0%+11.8%
Neutral431+3.8%+7.7%+19.4%+45.1%
Distribution67+1.5%+6.9%+13.0%+42.7%
Selling7Too few readings yet

Average WGS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.

Accumulation zone: Institutional interest building. About the five zones →

See every daily GekkoIndex reading plotted over the WGS price, zone by zone.Track WGS in Gekko

Is GeneDx stock overvalued? Gekko Fair Value

GeneDx trades 26.3% below Gekko Fair Value of $86.61, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what GeneDx shares are worth, recalculated every trading day.

$86.61

Gekko Fair Value, Oct 10, 2026

26.3% Undervalued

At the end of Aug 2026 the price was 1.4% above the estimate.

Gekko Fair ValueShare price, month end
$87$67Aug 2026SepOct 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open WGS in Gekko

GeneDx insider and Congress trading

No open-market insider purchases were filed for GeneDx, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for WGS in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every WGS insider filing, plotted on the chart in Gekko.Open WGS in Gekko

Congress trades last 90 days

No trades in WGS were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for WGS, plotted on the chart in Gekko.Open WGS in Gekko

GeneDx earnings: next date and track record

GeneDx reports on Oct 27, 2026 (15 days away), and beat the EPS estimate in 7 of its last 8 reports.

7 of 8reports beat the EPS estimate
±27.7%average move across the report
5 of 8reports followed by a gain

Share-price move across each report

+48.4%Oct ’24+45.8%Feb ’25−46.7%Apr ’25+21.9%Jul ’25+0.8%Oct ’25−1.7%Feb ’26−47.2%May ’26+8.9%Aug ’26

Last earnings call, Aug 3, 2026 AI summary

What they said
GeneDx reported a solid Q2 2026 with total revenue of $114.4M (up 11% YoY), 30,785 exome/genome tests (32% YoY growth), improved gross margin (70%), and a return to profitability one quarter earlier than expected (adjusted net income $0.4M). Management reaffirmed full-year 2026 guidance and set a new operational focus on three priorities: optimizing unit economics, growing exome/genome utilization, and delivering scaled products while managing capital. The company cited mix dynamics (genome mix down q/q to ~32% from ~40% in Q1), a blended average reimbursement rate (ARR) baseline of $3,258 per test, and significant opportunities to increase realized payments by improving payer coverage, implementing payer-specific workflows, and improving collections. Carelon’s policy expanded commercial genome coverage from 47% to 87% in one quarter, and Medi‑Cal published a genome fee effective July 1; both are expected to help collections but with payment lags. GeneDx highlighted operational improvements (wet and dry lab efficiencies, increased sequencing fleet, automation/AI for dry lab), sales-force expansion and early traction in new channels (general pediatrics, prenatal), and a bridge product (reflex) that is being used to manage mix. Management expects collection rates roughly flat in Q3 with meaningful improvements beginning in Q4 and more material benefit in 2027, sees genome mix ~30% in H2, expects Q3 cash outflow (~$10M) and Q4 returning to cash flow generation, and anticipates sustained cash generation in 2027.
Guidance
Reaffirmed full-year 2026 guidance (no change). Q3: expect collection rates roughly flat vs Q2; meaningful collection improvements beginning in Q4. Expect genome mix to hover around ~30% (maybe slightly lower) in H2 2026. Q3 operating cash flow outflow of approximately $10M; Q4 returning to cash flow generation. Long-term (2027+): expect material upside from higher collection rates and strong sustained cash generation.
Risks flagged
Key risks noted include low current outpatient insurance-based collection rates (company cites ~32% blended collection on genome), variability and lag between payer coverage and actual payment/operationalization, payer-specific administrative hurdles (prior auths, medical necessity documentation), uncertainty about timing for MCOs to follow Medi‑Cal policy, execution risk in building payer-specific workflows and revenue-cycle management, and competition in the genomic testing market. These risks could delay or reduce the expected uplift in realized reimbursement and cash flow.
ReportedEPSSurpriseRevenueSurpriseMove
Aug 3, 2026$0.01
est −$0.19		+105.3%$114.4M
est $111.0M		+3.1%+8.9%
May 4, 2026−$0.28
est −$0.05		−465.7%$102.3M
est $112.5M		−9.1%−47.2%
Feb 23, 2026$0.14
est $0.09		+58.0%$121.0M
est $120.3M		+0.6%−1.7%
Oct 28, 2025$0.49
est $0.28		+75.0%$116.7M
est $120.5M		−3.1%+0.8%
Jul 29, 2025$0.50
est $0.10		+400.0%$102.7M
est $98.64M		+4.1%+21.9%
Apr 30, 2025$0.28
est $0.11		+154.5%$87.12M
est $85.32M		+2.1%−46.7%
Feb 18, 2025$0.70
est $0.04		+1,650.0%$95.64M
est $78.98M		+21.1%+45.8%
Oct 29, 2024$0.04
est −$0.19		+121.1%$76.87M
est $80.22M		−4.2%+48.4%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

GeneDx stock forecast and analyst price targets

Analysts’ average 12-month price target for GeneDx is $93.50, +46.5% from the last close, from 7 firms rating the stock in the last 90 days.

$93.50consensus 12-month target, +46.5% from the last close
Low $63High $103
Buy7
Hold0
Sell0

Each firm’s latest rating in the last 90 days: 7 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Oct 1GuggenheimBuy, maintained$83+30.1%
Sep 22Craig-HallumBuy, maintained$103+61.4%
Aug 4Piper SandlerBuy, maintained$63−1.3%
Aug 4Craig-HallumBuy, maintained$103+61.4%
Aug 4Wells FargoBuy, maintained$75+17.5%
+1.0%average 20-day move after past Accumulation readings
+2.0%average move over the next 20 trading days in the last 5 years
±9.3%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

GeneDx seasonality: the next 20 trading days

Over the next 20 trading days from Oct 10, GeneDx averaged +2.0% across the last 5 years, rising in 4 of them.

Next 20 trading days, by year

+6.1%2021+2.1%2022−51.7%2023+36.7%2024+14.8%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days+0.4%2 of 5
Next 10 trading days+2.2%3 of 5
Next 15 trading days+7.0%4 of 5
Next 20 trading days+2.0%4 of 5
Next 30 trading days−11.6%2 of 5

For scale, WGS’s typical 20-trading-day move in either direction is about 19.8%.

GeneDx market cap and key statistics

GeneDx’s market cap is $1.90B and revenue of $454.4M over the last twelve months.

Valuation

Market cap
$1.90B
Forward P/E
63.3
EPS, TTM
−$3.63
Gekko Fair Value
$86.61

Trading

Volume
490,417
Avg volume, 20 days
839,135
52-week high
$170.87
52-week low
$32.21
Shares outstanding
29.82M

Financials

Revenue, TTM
$454.4M
Profit margin
-23.4%
Return on equity
-40.8%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
1.97
Typical daily move
±9.3%
Typical 20-day move
±19.8%

GeneDx stock news this week

3 headlines about GeneDx from the past week, newest first, each linking to the publisher.

GeneDx peers

GeneDx’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LHLabcorp+1.7%Neutral2.5% below
GHGuardant Health−3.2%Accumulation10.0% below
SOLVSolventum−1.9%Accumulation20.5% below
BTSGBrightSpring Health Services−1.0%Neutral2.8% above
EHCEncompass Health+0.6%Neutral7.3% above
DVADaVita+1.2%Neutral14.6% below

A peer links to its own page where one exists.

In the Buying zone today

VZTMUSTBMYINGBCS

Reporting earnings this week

JPMJNJUNHGSWFCC

Popular on Gekko

NVDATSLAMSFTAMZNMETAGOOGL

GeneDx stock FAQ

What is GeneDx’s market cap?

GeneDx’s market cap is $1.90B at the Oct 12, 2026 close of $63.82, with 29.82M shares outstanding.

What is the GeneDx stock forecast?

The consensus analyst 12-month price target for GeneDx is $93.50, +46.5% from the last close. Of the 7 firms that rated the stock in the last 90 days, 7 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is GeneDx stock overvalued or undervalued?

On Gekko’s estimate GeneDx is undervalued: the Oct 12, 2026 close of $63.82 is 26.3% below Gekko Fair Value of $86.61. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does GeneDx report earnings next?

GeneDx is expected to report on Oct 27, 2026 (15 days away). Analysts expect earnings of $0.07 per share on revenue of $122.9M. GeneDx beat the earnings estimate in 7 of its last 8 reports, moving 27.7% on average across the report.

What is GeneDx’s 52-week high and low?

GeneDx’s 52-week high is $170.87 and its 52-week low is $32.21; it closed at $63.82 on Oct 12, 2026, −49.7% over the past year. Over the last five years the shares peaked at $302.94 on Nov 4, 2021.

Is GeneDx stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and seasonality), 1 as mixed (trend) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

Built and overseen by Jared Mann

Founder of Gekko.app. Jared has traded stocks and ETFs for more than 20 years and has a financial industry background.

About GekkoHow Gekko’s data worksReport an error

See GeneDx the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,408 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.